Research Topics
Genomes and GenesSpecies | Christine D BergSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)Federico Canzian
German Cancer Research Center DKFZ, Heidelberg, Germany
BMC Cancer 9:257. 2009..We studied the association between breast cancer risk and polymorphisms in genes that code for GNRH1 and its receptor (GNRHR) in the large National Cancer Institute Breast and Prostate Cancer Cohort Consortium (NCI-BPC3)...
The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: the prostate cancer screening results in contextChristine D Berg
Early Detection Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20852, USA
Acta Oncol 50:12-7. 2011..The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) was conducted in sites around USA during a period of marked secular changes in the use of prostate specific antigen (PSA) screening for prostate cancer...- A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancerClaire S Zhu
Division of Cancer Prevention, National Cancer Institute, National Institute of Health, Bethesda, MD 20892 7346, USA
Cancer Prev Res (Phila) 4:375-83. 2011..Thus, biomarker panels discovered in diagnostic samples may not validate in prediagnostic samples; utilizing prediagnostic samples for discovery may be helpful in developing validated early detection panels... - Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial CohortJames V Lacey
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA
BMC Cancer 9:84. 2009..We therefore evaluated known risk factors for breast cancer in a cancer screening trial that does not have breast cancer as a study endpoint but is large enough to provide numerous analytic opportunities for breast cancer... - The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinomaSummer S Han
Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 7231, USA
Hum Mol Genet 21:1190-200. 2012..72 × 10(-9), per-allele OR = 1.28, 95% CI: 1.18-1.39) In conclusion, we report that chromosome 2p21 harbors a complex genetic architecture for common RCC risk variants... - Estrogen metabolism and risk of breast cancer in postmenopausal womenBarbara J Fuhrman
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD 20892, USA
J Natl Cancer Inst 104:326-39. 2012.... - Cumulative incidence of false-positive results in repeated, multimodal cancer screeningJennifer Miller Croswell
Office of the Director, Office of Disease Prevention, National Institutes of Health, 6100 Executive Blvd, Suite 2B 03, Bethesda, MD 20892, USA
Ann Fam Med 7:212-22. 2009..We sought to determine the cumulative risk of a false-positive screening result and the resulting risk of a diagnostic procedure for an individual participating in a multimodal cancer screening program... - Performance of common genetic variants in breast-cancer risk modelsSholom Wacholder
Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 5050, MSC 7244, Bethesda, MD 20892, USA
N Engl J Med 362:986-93. 2010..Genomewide association studies have identified multiple genetic variants associated with breast cancer. The extent to which these variants add to existing risk-assessment models is unknown... 
Ovarian cancer screening in women with a family history of breast or ovarian cancerJames V Lacey
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20892, USA
Obstet Gynecol 108:1176-84. 2006..To evaluate positive predictive values of CA 125 or transvaginal ultrasonography screening for ovarian cancer according to family history of breast or ovarian cancer...- A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1)Gilles Thomas
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland, USA
Nat Genet 41:579-84. 2009..1 (rs999737; P = 1.74 x 10(-7)) localizes to RAD51L1, a gene in the homologous recombination DNA repair pathway. We also confirmed associations with loci on chromosomes 2q35, 5p12, 5q11.2, 8q24, 10q26 and 16q12.1... - Radiation-related cancer risks from CT colonography screening: a risk-benefit analysisAmy Berrington de Gonzalez
Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, Bethesda, MD 20892, USA
AJR Am J Roentgenol 196:816-23. 2011..The purpose of this study was to estimate the ratio of cancers prevented to induced (benefit-risk ratio) for CT colonography (CTC) screening every 5 years from the age of 50 to 80 years... - Circulating insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 levels and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohortCatherine Schairer
Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, 20852 7244, USA
Horm Cancer 1:100-11. 2010..Further research should emphasize larger studies, including pooled analyses, analyses by cancer subtype, improved exposure assessment, and possible mechanisms... - Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registriesAmy Berrington de Gonzalez
Radiation Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892, USA
Lancet Oncol 12:353-60. 2011..We aimed to estimate the proportion of second cancers attributable to radiotherapy in adults with data from the US Surveillance, Epidemiology and End Results (SEER) cancer registries... - Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trialSarah J Nyante
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Rockville, MD 20852, USA
Gynecol Oncol 120:474-9. 2011..We examined relationships between histopathologic diagnoses, false-positive test group, and participant and screening test characteristics... - Workshop on imaging science development for cancer prevention and preemptionGary J Kelloff
NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
Cancer Biomark 3:1-33. 2007..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer... - Genetic variation on 9p22 is associated with abnormal ovarian ultrasound results in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialNicolas Wentzensen
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America
PLoS ONE 6:e21731. 2011..The single nucleotide polymorphism (SNP) markers localize to the BNC2 gene, which has been associated with ovarian development... - The National Lung Screening Trial's Endpoint Verification Process: determining the cause of deathPamela M Marcus
Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, Bethesda, MD 20892 7354, USA
Contemp Clin Trials 32:834-40. 2011..We describe the National Lung Screening Trial's (NLST's) death review approach, the Endpoint Verification Process (EVP), which strives to minimize errors in assignment of cause of death due to lung cancer... - Lung cancer screening: promise and pitfallsJudith J Smith
Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, US Department of Health and Human Services, Bethesda, MD 20892, USA
Semin Oncol Nurs 24:9-15. 2008..To provide an overview of the status of lung cancer screening... - Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trialD Michal Freedman
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, MD 20892 7238, USA
Cancer Epidemiol Biomarkers Prev 17:889-94. 2008.... - Prostate-specific antigen screening for prostate cancer in older men in the United States of AmericaAmanda Black
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20852, USA
Gerontology 58:331-6. 2012..We discuss the current PSA screening recommendations and practices in the USA and the benefits and harms of screening older populations... - Fine mapping of 14q24.1 breast cancer susceptibility locusPhoebe Lee
Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Hum Genet 131:479-90. 2012..Therefore, we conclude that rs999737 is an optimal tag SNP for common variants in the 14q24.1 region and thus narrow the candidate variants that should be investigated in follow-up laboratory evaluation... - Thyroid cancer rates and 131I doses from Nevada atmospheric nuclear bomb tests: an updateEthel S Gilbert
Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 7238, USA
Radiat Res 173:659-64. 2010..Nevertheless, the study adds support for an increased risk of thyroid cancer due to fallout, although the data are inadequate to quantify it... - Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3Mark P Purdue
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, Maryland, USA
Nat Genet 43:60-5. 2011..31 for rs4765623, which maps to SCARB1, the scavenger receptor class B, member 1 gene (P = 2.6 × 10⁻⁸). Our study reports previously unidentified genomic regions associated with RCC risk that may lead to new etiological insights... - Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered?Paul F Pinsky
Detection Branch, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd, EPN 3064, Bethesda, Maryland, 20892, USA
J Med Screen 19:154-6. 2012.... - Low-dose lung computed tomography screening before age 55: estimates of the mortality reduction required to outweigh the radiation-induced cancer riskAmy Berrington de Gonzalez
Division of Cancer Epidemiology and Biostatistics, National Cancer Institute, Bethesda, MD 20892, USA
J Med Screen 15:153-8. 2008..e. the efficacy) needed to outweigh these risks for never and current-smokers. The risk of radiation-induced breast cancer was also estimated for women... - Ovarian volume: determinants and associations with cancer among postmenopausal womenMark E Sherman
Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20892, USA
Cancer Epidemiol Biomarkers Prev 15:1550-4. 2006..Confirmation of these findings in future studies, including analyses of serum hormone levels and tissues, may provide insights into hormonal carcinogenesis among older women... - Methods for etiologic and early marker investigations in the PLCO trialRichard B Hayes
Division of Cancer Epidemiology and Genetics, National Cancer Institute, EPS 8114, Bethesda, MD 20892, USA
Mutat Res 592:147-54. 2005..g., diet), biochemical, and genetic factors. Early detection studies focus on blood-based biologic markers of early disease. Clinical epidemiology is also an important component of the PLCO trial...